Premium
Efficacy of 3,4‐Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study
Author(s) -
Wirtz PW,
Verschuuren JJ,
Dijk JG,
Kam ML,
Schoemaker RC,
Hasselt JGC,
Titulaer MJ,
Tjaden UR,
Hartigh J,
Gerven JMA
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.35
Subject(s) - pyridostigmine , lambert eaton myasthenic syndrome , myasthenia gravis , crossover study , placebo , pyridostigmine bromide , acetylcholine , neuromuscular transmission , medicine , pharmacology , anesthesia , chemistry , alternative medicine , pathology
3,4‐Diaminopyridine and pyridostigmine are widely used to treat Lambert–Eaton myasthenic syndrome (LEMS), either alone or in combination. 3,4‐Diaminopyridine enhances the release of acetylcholine at the neuromuscular synapse, and pyridostigmine inhibits the degradation of this neurotransmitter. Although this could lead to a synergistic effect on neuromuscular transmission, no studies have compared the effects of these drugs in patients with LEMS. Therefore, we performed a placebo‐controlled, double‐dummy, double‐blind, randomized, crossover study in nine patients with LEMS. Clinical Pharmacology & Therapeutics (2009); 86 , 1, 44–48 doi: 10.1038/clpt.2009.35